butyrophilin subfamily 2 member A2Genealiases: BT2.2 · BTF2 · BTN2.2
Q-omics provides the consensus-scored BTN2A2 profile across patient tissues and cancer cell-line models. BTN2A2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BTN2A2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, BTN2A2 RNA expression shows 19,367 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where BTN2A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTN2A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTN2A2 survival associations across molecular data types. BTN2A2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTN2A2 RNA expression–survival associations across cancer types. High BTN2A2 expression shows unfavorable associations in ACC and LGG, but favorable associations in LUAD, SCLC, KIRC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for BTN2A2 RNA expression.
This table summarizes BTN2A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BTN2A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTN2A2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, HNSC and LIHC. The KIRC box plot shows higher BTN2A2 RNA expression in tumor versus normal tissue (log2 FC = +1.292, t-test p < 0.001).
This table shows molecular features associated with BTN2A2 in patient tissues and cancer cell lines. In patient samples, BTN2A2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BTN2A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
